A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL9
about
The role of maintenance therapy in acute promyelocytic leukemia in the first complete remissionThe role of maintenance therapy in acute promyelocytic leukemia in first complete remissionCuring all patients with acute promyelocytic leukemia: are we there yet?Arsenic trioxide cooperates with all trans retinoic acid to enhance mitogen-activated protein kinase activation and differentiation in PML-RARalpha negative human myeloblastic leukemia cells.Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapyATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia.Arsenic trioxide - An old drug rediscovered.Acute myeloid leukemia, version 2.2013.Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell countsMicroRNA-27a Contributes to Rhabdomyosarcoma Cell Proliferation by Suppressing RARA and RXRA.Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid eraNewly diagnosed acute promyelocytic leukemiaBudgetary impact of treating acute promyelocytic leukemia patients with first-line arsenic trioxide and retinoic acid from an Italian payer perspective.Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient.Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic LeukemiaOral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for TransplantationChromosomal abnormality of acute promyelocytic leukemia other than PML-RARA: a case report of acute promyelocytic leukemia with del(5q)Emerging new approaches for the treatment of acute promyelocytic leukemia.Treatment of acute promyelocytic leukemia for older patients.Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicinTreatment outcomes in relapsed acute promyelocytic leukemia patients initially treated with all-trans retinoic acid and arsenic compound-based combined therapies.Bayesian network meta-analysis comparing five contemporary treatment strategies for newly diagnosed acute promyelocytic leukaemia.Acute promyelocytic leukemia: what are the treatment options?Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives.Recent advances in the diagnosis and management of childhood acute promyelocytic leukemiaAdvances in therapies for acute promyelocytic leukemia.Managing acute promyelocytic leukemia without conventional chemotherapy: is it possible?Current treatment strategy of acute promyelocytic leukemia.Provocative pearls in diagnosing and treating acute promyelocytic leukemia.Acute promyelocytic leukemia: do we have a new front-line standard of treatment?What is the standard regimen for patients with acute promyelocytic leukemia?Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction.Recent advances in acute promyelocytic leukaemia.Current standard treatment of adult acute promyelocytic leukaemia.Combined chemotherapy for acute promyelocytic leukemia: a meta-analysis.Current management of newly diagnosed acute promyelocytic leukemia.Autologous hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission: outcomes before and after the introduction of arsenic trioxide.Chronic Myeloid Leukemia Developing After Successful Treatment of Acute Promyelocytic Leukemia.Evaluation of the efficacy of maintenance therapy for low-to-intermediate-risk acute promyelocytic leukemia in molecular remission: A retrospective single-institution study.Successful Control of Disseminated Intravascular Coagulation by Recombinant Thrombomodulin during Arsenic Trioxide Treatment in Relapsed Patient with Acute Promyelocytic Leukemia.
P2860
Q24200224-A739232B-DFC3-4C99-923B-01581C666CA9Q24203970-F62BD3F2-FD65-4873-8A83-80A65C1AD172Q33613426-342EA8E6-0DDE-4150-9DEE-2E1D8F5134FFQ33628050-F26CCD9E-85E6-4234-9438-BF0405B085C9Q33781722-E1048600-9DE3-4C15-A5FB-7EAE8AF798D9Q34046794-E8E86830-E856-4E4A-A464-0E3C2DEE3C82Q34054167-5C0125D9-5137-4D2C-BA04-4B1EEB95404BQ34165330-8CC50DDD-ABA0-462E-B530-70B4C5B7DFE1Q35051695-67C981B1-1CB6-4A48-8E17-41E4F7EAC674Q35542078-98D929DD-953B-4E23-92D6-4DF025C58216Q35640734-26105823-6AD4-40F1-9F4A-9752F9FEC526Q35640773-A16DE56E-F3C2-4A98-84D6-8DD2874C39F5Q35743980-069DF537-9785-4F53-9A11-A3B7CB05BF94Q35800229-534550D2-3E13-43BA-86FC-9F01AFA749FDQ35904994-5816143E-6B5B-4640-873A-725CBA9AA212Q36075433-81C95425-341C-4CA5-B234-630554AEC43FQ36154444-5FD560F5-DF34-498E-AC64-8FC7ADD3FB1DQ36612619-B9775DDF-E9BB-4CCA-85AC-20F85359805EQ36672084-FC9D6442-F724-4B78-908A-DE8EBA08CC44Q36938551-A96FCE39-6324-4DF0-BCA2-9B80A9877E39Q37388701-5EB86574-9FDE-4499-926D-63666FDB1026Q37565126-0C1D4329-042E-4DDC-950B-7199192D1B03Q37693929-C0B98021-6CD0-48FF-9296-8A43AA461F07Q37712353-A18E22E1-CE9A-4AB1-9BC9-3F305CD35844Q37899041-9397D0F2-DD59-4394-86AA-E89A28CCDDAFQ37905921-AF2A0FF9-B6DA-44CE-9E12-3427498A8A21Q37908158-E53F71CF-BDBD-4C83-8679-0409EB0A05CEQ37971327-FF7B9094-F718-4A5E-9AD5-078E4A8FF16AQ38034229-DF7A644B-312D-4C9E-8136-6B15AC244160Q38132719-7ED6C39D-39FC-40BB-8D9E-FF15C7213701Q38204310-B97E5C80-6D3E-4D87-AE5B-72C88A7D766EQ38221006-25EF211A-302C-41C5-8EDA-4DB336C7CE0BQ38556985-39E417B6-EC8C-42EF-B906-76DA39FAF44BQ38674575-97316A28-BB81-4EC1-A1D3-7D12B7CC4FE9Q38798789-F416A5AA-E890-4B63-9EEA-9C2FD1749E61Q38809825-45173D54-CBBC-4595-AE4E-BC503B469FEFQ39323997-F3D0A5F7-FFD7-4943-8758-131D0B034439Q41811411-F92F9A18-169D-42AA-848F-47399110505CQ42259192-B64C280C-03E6-4722-9325-376A0F6ADE1FQ42326565-68915AFD-7E1F-4ED7-A555-ABA6ADF617BF
P2860
A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL9
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
A randomized study with or wit ...... kemia Study Group (JALSG) APL9
@ast
A randomized study with or wit ...... kemia Study Group (JALSG) APL9
@en
A randomized study with or wit ...... pan Adult Leukemia Study Group
@nl
type
label
A randomized study with or wit ...... kemia Study Group (JALSG) APL9
@ast
A randomized study with or wit ...... kemia Study Group (JALSG) APL9
@en
A randomized study with or wit ...... pan Adult Leukemia Study Group
@nl
prefLabel
A randomized study with or wit ...... kemia Study Group (JALSG) APL9
@ast
A randomized study with or wit ...... kemia Study Group (JALSG) APL9
@en
A randomized study with or wit ...... pan Adult Leukemia Study Group
@nl
P2093
P921
P1433
P1476
A randomized study with or wit ...... kemia Study Group (JALSG) APL9
@en
P2093
Akihiro Takeshita
Fumiharu Yagasaki
Hitoshi Kiyoi
Japan Adult Leukemia Study Group
Katsuji Shinagawa
Kentaro Horikawa
Masako Iwanaga
Masatomo Takahashi
Masaya Okada
Miki Nishimura
P356
10.1182/BLOOD-2006-08-043992
P407
P577
2007-03-20T00:00:00Z